Owkin: Co-founded in 2016 by Thomas Clozel, oncologist, and Gilles Wainrib, Professor of Artificial Intelligence, OWKIN develops innovative services and solutions to accelerate the discovery of new treatments and advance personalized medicine. The growing accumulation of data, combined with the recent revolution in artificial intelligence, makes it possible to discover new therapeutic targets, to predict the effect of molecules and to help doctors give the right treatment to the right person. At the heart of the medicine of the future, OWKIN counts among its customers and partners pharmaceutical companies, hospitals specializing in the treatment of cancer like the Institut Curie, and academic research laboratories, in France and abroad. Inserm: The Institut national de la santé et de la recherche médicale is the French National Institute of Health and Medical Research. As the only French public research institute to focus entirely on human health, Inserm has the responsibility for the strategic, scientific and operational coordination of biomedical research. Inserm brings together 15,000 researchers, engineers, technicians and administrative staff, with a common goal: to improve the health of all through the advancement of knowledge about life and disease, innovation in treatment and public health research. The Institute is distinguished by the scientific excellence of its teams, but also by its ability to provide translational research from the research laboratory to the patient's bedside. Today, Inserm is Europe's leading academic research institution in the biomedical field, with nearly 12,000 publications a year, and the world's second largest behind the intramural National Institutes of Health (NIH). Inserm is also the world's 9th most innovative public research organization, according to the Thomson-Reuters 2016 ranking.